Arbitel Trio 50 Tablet 10

When used in pregnancy during the second and third trimesters, telmisartan can cause injury and even death to the developing fetus.

Moreover, metoprolol crosses the placenta. Neonates born to mothers who are receiving metoprolol during pregnancy may be at risk for hypotension, hypoglycemia, bradycardia, and respiratory depression.

Therefore, when pregnancy is detected, Arbitel-Trio 50 tablet should be discontinued as soon as possible.

Inform your doctor of your pregnancy if being prescribed this medicine.

It is not known whether telmisartan is excreted in human breast milk. Metoprolol passes in breast milk.

Due to the potential for adverse effects on the nursing infant, your doctor should decide whether to discontinue nursing or discontinue the medication, taking into account the importance of the medication to the mother.

Alcohol interferes with the extended-release properties of metoprolol succinate. It is advisable not to consume alcohol when using this medicine.

Metoprolol succinate is metabolized by the liver, hence metoprolol blood levels are likely to increase substantially with poor liver function.

Therefore, therapy should be initiated at doses lower than those recommended for a given indication, for patients with impaired liver functioning.

Inform your doctor if suffering from any liver condition before starting this medicine.

If you have any kidney problems, it is important to inform your doctor before taking this medicine. Your doctor will determine if Arbitel-Trio 50 Tablet is suitable for you and may adjust the dosage accordingly.

This medicine may cause dizziness or fatigue in some individuals. If you experience these side effects, avoid operating machinery or driving until you know how the medicine affects you.

Inform your doctor if you have any allergies, especially to cilnidipine, metoprolol succinate, or telmisartan.

The safety and effectiveness of metoprolol succinate have not been established in patients < 6 years of age, and telmisartan has not been established in patients < 18 years old.

Arbitel Trio-50 Tablet, therefore, is not recommended for use in children. Consult a paediatrician for appropriate medications for children with hypertension.

Patients above 65 years of age may be more sensitive to the effects of this medicine due to reduced hepatic, renal or cardiac function.

Regular monitoring by a doctor is important to ensure safety and effectiveness.